SPARC enters into agreement with Johns Hopkins and Czech research instituteIllustrative image – not actual.

Sun Pharma Advanced Research Company (SPARC) has entered into an agreement with Johns Hopkins University (JHU) and The Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences (IOCB) to exclusively license SCD-153, including all patents and patent applications owned or controlled by licensors IOCB.

SCD-153 is a topical drug for the treatment of alopecia areata (involving hair loss), developed jointly by SPARC, JHU and IOCB. SPARC had evaluated SCD-153 under a material transfer agreement (MTA) and then entered into an Option to License Agreement with the licensors. Further, its Investigational New Drug (IND) was approved by the Drug Controller General of India (DCGI).

The licensing of SCD-153 marks a successful collaboration between SPARC and an academic institute under its outreach program with academia. Topical SCD-153, upon successful development, can provide an important option to clinicians and patients for the treatment of Alopecia Areata.

← All latest storiesBack to top →